UMB Capital completed the majority sale of portfolio company KCAS Bioanalytical and Biomarker Services (KCAS). Vitruvian Partners, an investment firm, recently acquired a majority ownership stake in KCAS, which is located in the Kansas City, KS, metropolitan area. Both management and current majority shareholder Konza Valley Capital (KVCI) are making a reinvestment in the company. The investment made by KVCI and UMB Capital assisted KCAS in increasing cash flow and accomplishing growth plans.
“We’ve had a fantastic experience working with KCAS as well as our other partners in this deal,” Andre Trudell, president of UMB Capital, said. “This project was a win for all parties, resulting in a profitable exit for KCAS and a positive business investment for UMBCC. We’re excited to continue as stakeholders and look forward to being part of Vitruvian Partners’ strategy and growth plan. While we work on projects nationwide, it always feels good to have success in the place we call home.”
“UMBCC was a significant partner in KCAS’ recent success in attracting a new investor to continue the company’s growth,” John Bucksath, CEO of KCAS, said. “UMBCC’s support and guidance over the investment period was critical for our company to be in a position to realize its market opportunity and accelerate growth.”
Since 2015, UMB Capital has assisted more than 50 companies with growth, acquisition, change of control and recapitalization via debt and equity investments. Recently, UMB Capital was recognized with an award from the Association for Corporate Growth – Houston for its role in providing subordinated debt and equity as part of the acquisition of Conco Holdings with investment partners Rising Point Capital of Chicago and Tecum Capital Partners of Pittsburgh.
